We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bruker Announces Acquisition of CMO InVivo Biotech
News

Bruker Announces Acquisition of CMO InVivo Biotech

Bruker Announces Acquisition of CMO InVivo Biotech
News

Bruker Announces Acquisition of CMO InVivo Biotech

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bruker Announces Acquisition of CMO InVivo Biotech"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bruker announced the acquisition of InVivo Biotech Services GmbH (www.invivo.de), headquartered in Hennigsdorf, Germany, near Berlin. InVivo Biotech is a molecular biology contract manufacturing organization (CMO), and a leading provider of monoclonal antibodies and recombinant proteins. InVivo Biotech also has significant experience in the development and production of innovative immunoassay components and research kits. In 2016, InVivo Biotech had revenues of approximately $5 million. Financial details of the transaction were not disclosed.

InVivo Biotech is an ISO 9001 certified CMO with over 18 years of experience in mammalian cell culture and protein production. The company is providing monoclonal antibodies and recombinant proteins for its CMO customers, which include diagnostics companies, major research institutes and biopharmaceutical companies. Its production covers quantities from milligrams to grams of purified antibodies, including all subclasses of IgGs, IgMs and IgEs derived from a collection of more than 3,000 different hybridoma clones producing human, rat or mouse monoclonals. InVivo Biotech uses proprietary media for serum-free cultivation to facilitate highly productive and cost-effective processes in a high cell density fermentation process with yields up to 500 mg of antibody per liter of culture per day.  

InVivo Biotech provides a complete range of biotech services, from cloning, screening and recombinant expression of antigens to the generation of hybridoma cell lines, and from characterization of antibodies to final production of the developed monoclonal antibodies. InVivo Biotech's selection of bacterial, insect and mammalian protein expression systems provides a wide range of choices for various applications, taking into account specific CMO customer needs concerning quantity, bioactivity, structure, post-translational modifications and purity. Recombinant proteins are produced via stable or transient transfection.

InVivo Biotech will continue to operate under its existing name and management team, and is looking forward to expanding its CMO partnering business with existing and additional CMO customers.

This major addition in expertise and infrastructure for consumables development, validation and production also will support Bruker´s strategy of expanding its microbiology assay menu for the MALDI Biotyper™ platform. Examples include Sepsityper™ IVD-CE assays for the fast identification of bacteria from positive blood cultures, RUO assays for selective testing of antibiotic resistance with the MBT-STAR™ assay family, and work-in-progress syndromic panels for the MALDI BioTyper as a multiplex PCR reader.

InVivo BioTech's kit development and production capabilities are expected to shorten time to market for such new assays. Furthermore, the expertise in monoclonal antibodies opens new possibilities to combine the specificity of antibody enrichment with the multi-channel information read-out via the MALDI Biotyper platform. Antibody enrichment strategies prior to MALDI Biotyper analysis enable new workflows and could further shorten microbial cultivation and time to result (TTR).

These capabilities also support Bruker's activities in translational pathology research with the MALDI Tissuetyper™.  Enzymes involved in the digestion and sample preparation of formalin-fixed-paraffin-embedded (FFPE) tissue are expected to complement the MALDI Tissuetyper platform. Moreover, monoclonal antibodies against new protein biomarkers identified in a MALDI Tissuetyper workflow can be efficiently produced at InVivo Biotech.

Dr. Wolfgang Weglöhner and Mr. Siegmund Karasch, the founders and Managing Directors of InVivo Biotech, commented: "We are very pleased by the expanded opportunities for our business using the global commercial infrastructure of Bruker, particularly for microbiology and pathology. With our molecular biology core products and CMO services, we anticipate significant growth and expansion opportunities."

Dr. Wolfgang Pusch, Executive Vice President at Bruker Daltonics, added: "We are systematically building up infrastructure to support our rapidly growing consumables business, especially in the field of microbiology and to prepare the market development in anatomical and molecular pathology. Together with our recently announced acquisition in the field of multiplex PCR-based microbiology testing, the InVivo Biotech acquisition is expected to greatly accelerate our assay and consumables business expansion."

Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.

Advertisement